Biotron Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BITRF research report →
Companywww.biotron.com.au
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company's lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of SARS-CoV-2, HIV-1, and hepatitis C virus infections. Biotron Limited was incorporated in 1999 and is headquartered in Sydney, Australia.
- CEO
- Michelle Miller GCertAppFin
- IPO
- 2013
- Employees
- 3
- HQ
- Sydney, NSW, AU
Price Chart
Valuation
- Market Cap
- $4.53M
- P/E
- -1.55
- P/S
- -3785.25
- P/B
- 1.11
- EV/EBITDA
- -0.85
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 190.21%
- Op Margin
- 222203.69%
- Net Margin
- 223061.06%
- ROE
- -119.12%
- ROIC
- -71.46%
Growth & Income
- Revenue
- $1.81M · 10.24%
- Net Income
- $-318,572 · 90.73%
- EPS
- $-0.00 · 92.11%
- Op Income
- $-338,751
- FCF YoY
- 84.06%
Performance & Tape
- 52W High
- $0.10
- 52W Low
- $0.00
- 50D MA
- $0.03
- 200D MA
- $0.01
- Beta
- -0.55
- Avg Volume
- 4.93K
Get TickerSpark's AI analysis on BITRF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our BITRF Coverage
We haven't published any research on BITRF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BITRF Report →